Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀå : Á¦Ç° À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°(ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«) - ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)
Pulmonary Arterial Hypertension Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
»óǰÄÚµå : 1482454
¸®¼­Ä¡»ç : Persistence Market Research
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,995 £Ü 7,227,000
Unprintable PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ º¹»ç, ÀμⰡ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 7,295 £Ü 10,555,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.
US $ 8,495 £Ü 12,291,000
PDF & Excel (Corporate User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste¿Í ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Persistence Market Research´Â Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀåÀÇ º¹ÀâÇÑ ¿ªÇÐ ¹× ¹Ì·¡ ±ËÀû¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇϱâ À§ÇØ Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀåÀ» ½ÉÃþÀûÀ¸·Î ºÐ¼®ÇÕ´Ï´Ù. ½ÃÀå µ¿ÇâºÎÅÍ ¼ºÀå Ã˸ÅÁ¦, ¾ïÁ¦¿äÀÎ, ½ÅÈï ÆÐÅÏ¿¡ À̸£±â±îÁö ÀÌ º¸°í¼­´Â 2024³âºÎÅÍ 2032³â±îÁö ±ÍÁßÇÑ Åë°è¿Í ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ÀλçÀÌÆ®

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀå - º¸°í¼­ ¹üÀ§ :

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀå¿¡´Â ÇÁ·Î½ºÅ¸»çÀÌŬ¸° ¹× ÇÁ·Î½ºÅ¸»çÀÌŬ¸° À¯»çü, ¿£µµ¼¼¸° ¼ö¿ëü ±æÇ×Á¦(ERA), Æ÷½ºÆ÷µð¿¡½ºÅͶó¾ÆÁ¦-5(PDE-5) ¾ïÁ¦Á¦, ¼ö¿ë¼º ±¸¾Æ´Ò»ê½ÃŬ¶ó¾ÆÁ¦(sGC) ÀÚ±ØÁ¦ µî ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½ÃÀåÀº º´¿ø, Ŭ¸®´Ð, Àü¹® Ä¡·á ¼¾ÅÍ µî ´Ù¾çÇÑ ÃÖÁ¾ »ç¿ëÀÚ¸¦ ´ë»óÀ¸·Î PAH °ü¸®¸¦ À§ÇÑ °í±Þ Ä¡·á ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü, PAHÀÇ À¯º´·ü Áõ°¡, Áúº´ ¹× Ä¡·á¹ý¿¡ ´ëÇÑ ÀÎ½Ä °³¼± µîÀÇ ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù.

½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀåÀº ¸î °¡Áö ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀο¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ÀÇÇÐ ¿¬±¸ÀÇ ¹ßÀü°ú »õ·Î¿î Ä¡·áÁ¦ÀÇ °³¹ßÀº Ä¡·á È¿°ú¿Í ȯÀÚ °á°ú¸¦ °³¼±Çϰí PAH Ä¡·áÀÇ Ã¤ÅÃÀ» ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ À¯ÀüÀû ¼ÒÀÎ, »ýȰ½À°ü º¯È­, µ¿¹Ý Áúȯ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ PAHÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, PAH¿Í ±× Ä¡·á¹ý¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, Á¤ºÎ Áö¿øÃ¥, Èñ±ÍÁúȯ ¿¬±¸¿¡ ´ëÇÑ ÀÚ±Ý Áö¿øÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí Çõ½ÅÀûÀÎ Ä¡·á¹ý °³¹ßÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀåÀº À¯¸ÁÇÑ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí, ³ôÀº Ä¡·áºñ, ½ÅÈï±¹ÀÇ ³·Àº ȯÀÚ ÀνÄ, ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç µî ¿©·¯ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖÀ¸¸ç, PAH Ä¡·áÀÇ °íºñ¿ëÀº ȯÀÚ¿Í ÀÇ·á ½Ã½ºÅÛ¿¡ °æÁ¦Àû ºÎ´ãÀ» °¡Áß½ÃÄÑ °í±Þ Ä¡·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù. Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹ ½ÃÀå¿¡¼­´Â PAH¿Í ±× Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³·±â ¶§¹®¿¡ Á¶±â Áø´Ü°ú Á¶±â Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÃÄ ½ÃÀå È®´ë¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀǾàǰ ½ÂÀÎ ¹× ±ÔÁ¤ Áؼö¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº Á¦Á¶¾÷ü¿¡ ±ÔÁ¤ Áؼö¿¡ ´ëÇÑ ºÎ´ãÀ» °¡Áß½ÃÄÑ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

½ÃÀå ±âȸ :

Æóµ¿¸Æ °íÇ÷¾Ð(PAH) ½ÃÀåÀº ±â¼ú Çõ½Å, Àü·«Àû Á¦ÈÞ, ½ÃÀå È®ÀåÀ» ÅëÇØ ¼ºÀå ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á, ÷´Ü Áø´Ü ±â¼ú, º´¿ë ¿ä¹ý°ú °°Àº »õ·Î¿î Æ®·»µå´Â Á¦Á¶¾÷üµéÀÌ »õ·Î¿î Ä¡·á Á¢±Ù¹ýÀ» ¸ð»öÇϰí ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖµµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àü·«Àû Á¦ÈÞ, ¿¬±¸ Çù·Â, ÀμöÇÕº´(M&A)À» ÅëÇØ ½ÃÀå ±â¾÷µéÀº Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ È®ÀåÇϰí, ±â¼ú ¿ª·®À» °­È­Çϸç, ÁÖ¿ä Áö¿ª¿¡¼­ ½ÃÀå ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í Èñ±ÍÁúȯ ¿¬±¸ ¹× Ä¡·á¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Áõ°¡´Â ½ÃÀå È®´ë¿Í ´Ù°¢È­¸¦ ÃËÁøÇϴ ȯ°æÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®µé

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ½ÃÀå ¸®½ºÅ©¿Í µ¿Çâ Æò°¡

Á¦4Àå ½ÃÀå ¹è°æ

Á¦5Àå ¼º°ø ¿­¼è°¡ µÇ´Â ¿ä¼Ò

Á¦6Àå ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ¼ö¿ä ºÐ¼®

Á¦7Àå ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ¸ÅÃ⠺м®

Á¦8Àå ¾àÁ¦ Ŭ·¡½ºº°, ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾Ð(PAH) ½ÃÀå ºÐ¼®

Á¦9Àå ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®, À¯Çüº°

Á¦10Àå Åõ¿© °æ·Îº°, ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾Ð(PAH) ½ÃÀå ºÐ¼®

Á¦11Àå Áö¿ªº°, ¼¼°èÀÇ Æóµ¿¸Æ¼º °íÇ÷¾Ð(PAH) ½ÃÀå ºÐ¼®

Á¦12Àå ºÏ¹ÌÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦14Àå À¯·´ÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦15Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦16Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦17Àå ÁÖ¿ä ±¹°¡ÀÇ Æóµ¿¸Æ¼º °íÇ÷¾ÐÁõ½ÃÀå ºÐ¼®

Á¦18Àå ½ÃÀå ±¸Á¶ ºÐ¼®

Á¦19Àå °æÀï ºÐ¼®

Á¦20Àå »ç¿ëµÈ ÀüÁ¦Á¶°Ç°ú µÎÀÚ¾î

Á¦21Àå Á¶»ç ¹æ¹ý

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Persistence Market Research presents an in-depth analysis of the Pulmonary Arterial Hypertension (PAH) Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2032.

Key Insights:

Pulmonary Arterial Hypertension Market - Report Scope:

The Pulmonary Arterial Hypertension Market encompasses various treatment options, including prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. This market caters to a wide range of end-users, including hospitals, clinics, and specialty treatment centers, offering advanced therapeutic solutions for managing PAH. Market growth is driven by factors such as advancements in medical research, rising prevalence of PAH, and increasing awareness about the disease and its treatments.

Market Growth Drivers:

The global Pulmonary Arterial Hypertension Market is bolstered by several key growth drivers. Advancements in medical research and the development of novel therapeutic agents enhance treatment efficacy and patient outcomes, driving the adoption of PAH therapies. Moreover, the rising prevalence of PAH, fueled by factors such as genetic predisposition, lifestyle changes, and comorbid conditions, creates significant demand for effective treatment options. Additionally, increasing awareness about PAH and its treatments, along with supportive government initiatives and funding for rare disease research, stimulates market growth and encourages the development of innovative therapies.

Market Restraints:

Despite its promising growth prospects, the Pulmonary Arterial Hypertension Market faces challenges related to high treatment costs, limited patient awareness in developing regions, and stringent regulatory requirements. The high cost of PAH treatments imposes financial burdens on patients and healthcare systems, potentially limiting access to advanced therapies. Furthermore, limited awareness about PAH and its symptoms in developing regions affects early diagnosis and treatment, hindering market expansion. Additionally, stringent regulatory requirements for drug approval and compliance impose compliance burdens on manufacturers, impacting market growth.

Market Opportunities:

The Pulmonary Arterial Hypertension Market presents lucrative growth opportunities driven by technological innovation, strategic collaborations, and market expansion. Emerging trends such as personalized medicine, advanced diagnostic techniques, and combination therapies inspire manufacturers to explore new treatment approaches and improve patient outcomes. Moreover, strategic partnerships, research collaborations, and mergers and acquisitions enable market players to expand their product portfolios, enhance their technical capabilities, and strengthen their market presence in key regions. Furthermore, growing investments in research and development, coupled with increasing government support for rare disease research and treatment, create a conducive environment for market expansion and diversification.

Key Questions Answered in the Report:

Competitive Intelligence and Business Strategy:

Leading players in the global Pulmonary Arterial Hypertension Market, including pharmaceutical companies and research institutions, focus on innovation, product differentiation, and market expansion to gain a competitive edge. These companies invest in research and development to develop advanced therapeutic agents, improve treatment efficacy, and explore new applications for PAH therapies. Moreover, strategic collaborations with research institutions, academic partners, and industry associations enable market players to access new technologies, expand their knowledge base, and accelerate product development efforts. Furthermore, emphasis on regulatory compliance, patient-centric initiatives, and corporate social responsibility enhances brand reputation and fosters long-term relationships with customers and stakeholders.

Key Companies Profiled:

Pulmonary Arterial Hypertension Market Research Segmentation:

By Drug Class

By Type

By Route of Administration

By Region

Table of Contents

1. Executive Summary

2. Market Overview

3. Market Risks and Trends Assessment

4. Market Background

5. Key Success Factors

6. Global Pulmonary Arterial Hypertension Market Demand Analysis 2019-2023 and Forecast, 2024-2032

7. Global Pulmonary Arterial Hypertension Market Value Analysis 2019-2023 and Forecast, 2024-2032

8. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Drug Class

9. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Type

10. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

11. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Region

12. North America Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

13. Latin America Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

14. Europe Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

15. Asia Pacific Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

16. Middle East and Africa Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

17. Key Countries Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

18. Market Structure Analysis

19. Competition Analysis

20. Assumptions and Acronyms Used

21. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â